12:43:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning COEGIN 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma
2024-02-29 Bokslutskommuniké 2023
2024-02-05 Extra Bolagsstämma 2024
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-06-15 Split COEGIN 100:1
2023-05-26 X-dag ordinarie utdelning COEGIN 0.00 SEK
2023-05-25 Årsstämma
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-27 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-20 X-dag ordinarie utdelning COEGIN 0.00 SEK
2022-05-19 Kvartalsrapport 2022-Q1
2022-05-19 Årsstämma
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Årsstämma
2021-05-21 X-dag ordinarie utdelning COEGIN 0.00 SEK
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-09-29 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-04-15 Inlösen COEGIN 0.1
2020-04-03 X-dag ordinarie utdelning COEGIN 0.00 SEK
2020-04-02 Årsstämma
2020-02-21 Bokslutskommuniké 2019
2019-11-23 Kvartalsrapport 2019-Q3
2019-09-09 Extra Bolagsstämma 2019
2019-08-24 Kvartalsrapport 2019-Q2
2019-06-18 X-dag ordinarie utdelning COEGIN 0.00 SEK
2019-06-17 Årsstämma
2019-03-16 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-20 Årsstämma
2018-06-07 X-dag ordinarie utdelning COEGIN 0.00 SEK
2018-02-23 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriBioteknik
Coegin Pharma är ett svenskt bioteknikföretag med dermakosmetiska projekt för hårtillväxt och hudpigmentering, samt läkemedelskandidater för behandling av hjärtinfarkt och leukemi. Gemensamt för projekten är att de har sin grund i patenterade teknologiplattformar och samarbeten med forskare och akademiker internationellt. Coegin Pharma har sitt huvudkontor i Lund.
2024-07-01 08:40:00

Coegin Pharma AB is pleased to announce that NGM's application process for the dual-listing of the company's shares on Börse Stuttgart is now completed. The first trading day on Börse Stuttgart is today, July 1, 2024.

This dual-listing is part of the Nordic Growth Market NGM AB ("NGM") Reach program, which leverages the primary listing in Sweden and makes shares primarily listed on NGM available through the "Nordic Growth Market" segment on Börse Stuttgart. Participation in NGM Reach incurs no significant costs for Coegin Pharma AB. 

Börse Stuttgart Group is the sixth-largest exchange group in Europe, with more than 2 million listed securities. This dual listing will provide Coegin Pharma with access to a broader network of investors through a truly European listing platform.

"We are pleased that our shares are now available to a broader investor base in Europe. We look forward to welcoming new shareholders and continuing our work on the pre-launch activities for our focus project on hair growth," says Jens Eriksson, CEO of Coegin Pharma.

Coegin's management will participate in a listing event in Stuttgart this fall. Communication activities to reach investors at Börse Stuttgart will also begin after the summer break.

In conjunction with the parallel listing on Börse Stuttgart, Coegin will start using English in its various communication channels to better reach an international audience. The company's website is already available in both Swedish and English.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotechnology company with several innovative groundbreaking drug candidates and dermocosmetic products. The company's projects have great potential for treating patients with serious diseases such as cancer and heart attack, as well as improving the quality of life for people in need of cosmetic products for hair growth. The strategy is to create value by developing and commercializing dermocosmetic products in partnership with leading commercial players and by early out-licensing "first-in-class" drug candidates to major pharmaceutical companies.

For further information: www.coeginpharma.com/en.